kras mutation and glutathion glynac mutation: from undruggable to druggable in cancer KRAS | OriGene Technologies Inc.
KRAS OriGene Technologies Inc. Pancreatic Cancer: Advances and Challenges PMC KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy What should we know about the 'undruggable' target KRAS? MedChemExpress Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges PMC
Pay in 4 interest-free payments of $6.43 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7




